Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
August 1, 2024
Earnings Call Speaker Segments
Larry Keusch
executiveHello, everybody, and thanks for joining us on the Teleflex Incorporated Second Quarter 2024 Earnings Conference Call. You can find the press release and the slides that go with this call on our website, teleflex.com. Just a note that a replay is going to be made available on our site, and anyone who wants to listen to it can find the information in this morning's press release. With us today are Liam Kelly, our Chairman, President and Chief Executive Officer, and Thomas Powell, our Executive Vice President and Chief Financial Officer. Liam and Tom are going to give prepared remarks, and after that we'll move into Q&A. Before we get started, I want to point out that a number of the topics we'll cover on this conference call will include forward-looking statements about future events, as described in the slides posted in the Investor Relations section of the Teleflex website; we want to warn you that these statements are indeed forward-looking in nature and come with risks and uncertainties, so actual events or results could turn out materially different. Among the factors that might lead actual results or events to differ materially are those we mention in today's press release, along with our filings with the SEC, such as our Form 10-K, which you can access on our website; with that, I'll hand things over to Liam for his remarks.
Liam Kelly
executiveLarry, thank you, and good morning to everyone joining us. On today's call, we'll go over what happened in the second quarter, highlight some commercial developments, and share where our 2024 financial guidance stands. But before we begin the usual business review, I want to flag something that took place after the second quarter ended. In our SEC filings, we've noted before that Italy's government passed a law in 2015. Under it, companies selling medical devices to the country's national health care system have to return part of their proportional revenue. That money helps cover shortfalls whenever government spending on medical devices exceeds the budget in a given year. How much a company owes is determined by how far above that year's regional caps the spending went. Together with many other makers of medical devices, we pushed back on whether this statute could actually be enforced, with our main argument being that the law violated the constitution. Up to now, no company has had to hand over these sums, because the court was still weighing the measure. Then on July 22, Italy's Constitutional Court handed down a decision against us, backing the legislation behind the payback requirement for medical device manufacturers. Even though Teleflex has been setting aside money annually starting in 2015, at this point we are adjusting our reserves upward so they match the entire sum we expect the Italian government to bill us for. During both the three-month and six-month periods that wrapped up on June 30, 2024, our EMEA segment recorded a $15.8 million boost to reserves tied to the Italian payback measure, with an offsetting decrease in revenue. Prior years accounted for $13.8 million of that overall reserve increase. Because the portion tied to earlier years isn't a standard revenue adjustment and won't happen again, it can't really help anyone meaningfully assess how our operations are doing. So to make it easier to evaluate our present operating performance and stack it up against how we've performed in the past, we took the $13.8 million from prior years out of our adjusted second quarter revenues. Teleflex's second-quarter revenue came in at $749.7 million, which represents a 0.9% GAAP increase compared with the same period last year. If you set aside the impact from the Italian payback measure in the prior year, adjusted revenue for Q2 reached $763.5 million — that's a 2.7% rise year-over-year on a reported basis and 3.44% higher in constant currency terms. Beyond the $13.8 million recorded during the quarter tied to earlier years, there's also $2 million in added reserves related to this measure, which serves to true up revenue from both the first and second quarters. Once you remove that unplanned $2 million reserve for the Italian measure, Q2 revenue actually landed just above the top end of the $760 million to $765 million guidance range we had given before. For the second quarter, adjusted earnings per share came in at $3.42, which was up 0.3% compared with the same period last year. Now, we're going to take a closer look at how our revenue performed during the second quarter. First, I'll walk through the revenue figures for our geographic segments in Q2. Unless I note otherwise, any growth number I cite is on an adjusted revenue and adjusted constant currency basis. In the Americas, we recorded $426.8 million in revenue, which represents a 0.6% increase over the prior year. As those of you who track Teleflex are aware, MSA revenues during the comparable period were booked in the Americas, which creates a difficult comparison against last year. The impact we felt in Q2 from the MSA termination was similar to the effect in Q1. EMEA generated $160.9 million, an increase of 9.8% relative to a year ago. That gain came from a deliberate approach aimed at broadening where Teleflex products are available geographically and lifting utilization across Europe. Now on to Asia, where revenue reached $87 million, up 4% from the same period last year. Results for the quarter were mainly shaped by weaker performance in South Korea tied to the continuing doctors strike; our estimate is that the doctors strike cut into APAC growth by roughly 5%. While we expect these doctors strike headwinds to persist for the rest of this year, we believe the effect will lessen. We still view Asia as a growth engine for Teleflex and look for roughly 10% growth there in 2024. Moving on to how each worldwide product category performed for Q2. When I talk about growth in these categories for the second quarter, I'll be referring to adjusted revenue on a year-over-year basis, adjusted for constant currency. Starting with vascular access, we saw a 4.8% increase compared to last year, reaching $181.1 million. Growth during this quarter was driven by our broad vascular access offerings, including our PICC portfolio and central access. One thing worth noting: the Endurance recall hit its one-year mark close to the end of the quarter, so beginning in the back half of 2024, comparisons will be normalized. Shifting to interventional, revenue hit $141.2 million, climbing 13.8% year-over-year; during the quarter, our geographic regions posted high single-digit growth or better, with the broad portfolio continuing to deliver, helped by growth drivers like MANTA, complex catheters, right heart catheters and intra-aortic balloon pumps. Now to anesthesia, where revenue grew 2.3% year-over-year to $102.5 million. Endotracheal tubes and intraosseous led the way. Notably, we hit the anniversary of the ET tube recalls near the quarter's end. Within our surgical business, revenue totaled $111.3 million, up 6.4% year-over-year. Underlying trends across our core surgical franchise remained solid, with our biggest franchises growing, paced by instrumentation and chest drainage. Despite continued pressure on sleeve gastrectomy volumes from GLP-1 medications, Titan Stapler's Q2 revenue gains contributed to both the growth trajectory of our surgical segment and the overall company average. Following our strategy, we maintained surgeon proctoring efforts and continued the rollout of our buttress kit that had launched earlier in 2024. Turning to interventional urology, revenue reached $83.1 million, up 7.1% compared to the same period last year. This growth was fueled by Barrigel sales after we acquired Palette Life Sciences in October 2023. Meanwhile, as anticipated, UroLift's growth was dampened by persistent headwinds on the service side and by sales force training related to Barrigel during the quarter. Sales for OEMs rose 5.8% compared to the same period last year, reaching $88.8 million. This quarter’s results show the order timing we mentioned before, with revenue we had expected in Q2 shifting into Q1. Other revenue for the second quarter fell 26.4% from a year earlier, coming in at $55.5 million. This year-over-year drop is mainly because of the planned December 2023 exit from the MSA by Medline. That wraps up what I have to say about second quarter revenue performance. Turning to some commercial and clinical developments. First, the intra-aortic balloon pump and catheter market. Since the FDA sent a letter on May 8 to health care providers regarding pump safety and quality at our primary rivals in that intra-aortic balloon pump space, we've noticed an uptick in quote activity. Patients in cardiogenic shock—a severe condition where the heart can't circulate enough blood for the body's requirements—are treated with intra-aortic balloon pump therapy. Roughly $250 million is spent each year worldwide on the intra-aortic balloon pump and catheter market, which is expanding at a low single-digit rate. It consists of balloon pumps, largely sold as replacements, plus single-use balloon catheters that are used to treat patients.
Liam Kelly
executiveTwo companies dominate this market, and Teleflex holds roughly one-third of it. According to 2023 market figures, Asia accounts for a bit more than one-third. North America makes up around one-third, while EMEA comes in at just under 30%. Right now we're working to expand how much pump and catheter manufacturing capacity we have, so we can support customers looking for another supplier. Going forward, we'll adjust that capacity carefully, guided by demand signals. Our view is that the largest incremental opportunity for Teleflex sits in the U.S. market, thanks to the wording in the FDA's letter to health care providers. To be specific, the agency advised health care facilities to move away from using rival devices and to find alternatives where they can; we also expect to keep gaining share in Asia, reflecting the team's solid execution across the last couple of years. Last, we aren't factoring in any significant share movement in Europe at this point, given a temporary suspension of their CE mark. As we look toward the second half of 2024, incremental pump revenue should arrive in the fourth quarter, reflecting the capital equipment sales cycle along with customer training. Given what cold activity is showing us right now, we expect incremental intra-aortic balloon pump and catheter revenue to continue at least through the first half of 2025. Tom will walk through what this opportunity means financially when we get to updated guidance for 2024. I'll now turn to an update on Palette, the most recent business we acquired. Palette Life Sciences has been part of the company for a little more than 9 months now, and I'm happy to say the acquisition is performing better than we anticipated. To start, integration keeps moving along nicely, covering employee onboarding, training and IT integration. Cross-functional product work, sales training and proctoring of the legacy UroLift sales force on Barrigel usage kept advancing, and our first tranche of dual-bag reps finished at the close of the second quarter. We're still on schedule to wrap up sales force integration entirely by the end of 2024. Next, Barrigel keeps building momentum in the U.S., with strong sequential revenue growth. Barrigel penetration into the rectal spacing market is continuing, and we expect more urologists and radiation oncologists to adopt the technology as time goes on. Because first half performance beat our expectations and our second half expectations are unchanged, we're raising 2024 revenue guidance for Palette to $70 million to $72 million, up from the prior $66 million to $68 million. For full year 2024, our interventional urology total revenue guidance still assumes roughly 7.5% growth. Last, a new product update: in our interventional access business, we recently secured FDA clearance for the Ringer perfusion balloon catheter. A limited market release is set for August, which keeps us on track with the second half 2024 timing we communicated previously. Just to remind everyone: Ringer features a distinctive balloon design that lets blood keep moving through a vessel even while that balloon is inflated. Our plan is to start out launching with a PTCA indication, though once our vessel perforation trial wraps up, we'll look into possibilities for expanding the label. That wraps up what I had prepared; at this point I'd like to hand things over to Tom, who will walk through our second quarter financial results in more detail. Tom?
Tom Powell
executiveThanks, Liam. Thanks, Liam. And good morning. With revenue performance already covered, I'll turn to margins. Adjusted gross margin came in at 60.8% for the quarter, up 180 basis points from the same period a year earlier. That year-over-year gain largely reflected the favorable gross margin effect of ending the MSA and buying Palette, along with favorable price and advantages from cost improvement efforts, partly offset by ongoing cost inflation. In the second quarter, adjusted operating margin reached 26.7%. That 10 basis point rise from a year ago was mainly driven by flow-through of the year-over-year gross margin improvement, partly offset by including Palette Life Science operating expenses, employee-related expenses and investments aimed at growing the business. During Q2, net interest expense reached $19.4 million, compared with $16.6 million during the same period last year. That increase versus the prior year stems from interest rates being higher than they were a year ago, along with a bigger average debt balance that helped finance the Palette acquisition, though stronger interest income partially offset this. For Q2 2024, our adjusted tax rate stood at 12.3%, whereas it was 10.8% in the comparable period last year. The increase in our adjusted tax rate from one year to the next is primarily due to extra expenses arising from the enactment of European Pillar 2 tax reform as well as the use of discrete items throughout the quarter. On the bottom line, adjusted earnings per share for Q2 came in at $3.42, representing a 0.3% gain relative to the previous year. Compared with the same period last year, earnings per share went up, and that figure takes in solutions plus our purchase of Palette Life Sciences together with the extra borrowing tied to it, the ending of the MSA, unfavorable currency movements, and a greater tax burden. Now for a few balance sheet and cash flow items. Over the 6 months, operations generated $204.5 million, versus $170.6 million a year earlier. That $33.9 million gain came mainly from better operating results and reduced cash going out for inventories, since supply chain conditions have improved and we are keeping inventory at more moderate levels. Partly working against the rise in net cash from operating activities were larger tax payments. Switching to the balance sheet. We finished the second quarter with $238.6 million in cash, up from $222.8 million at the close of 2023. That growth in our cash position largely reflects cash generated by operations, partially offset by capital expenditures and repayments on debt. Our net leverage stood at roughly 1.6x when the quarter ended. Moving on to capital allocation, alongside today's second quarter earnings announcement, we disclosed that our Board of Directors has approved a program to buy back as much as $500 million of our common stock. As part of that authorization, we are kicking off an accelerated share repurchase of $200 million, which we expect to carry out on August 2. For a long time, we've been reviewing how we deploy capital, and buybacks have come up in those conversations many times before. Reinvesting in the business remains priority number one, but the company itself is not static. Today, Teleflex has a broad portfolio of products that are essential to medicine and tied to critical care procedures; we are directing money toward growth drivers, launching new offerings to refresh our lineup and extend our reach into more geographies. In our view, now is the right time to bring an additional element into our disciplined capital deployment framework. The way we allocate capital reflects both the strong free cash flow we've produced over many years and the confidence we hold about what lies ahead. Through the years, our capital allocation approach has been aimed at thoughtful deployment of capital toward high-return opportunities, M&A among them; solid stewardship of our balance sheet; and steady dividend payments. As of today, the share repurchase authorization along with the subsequent planned launch of the ASR lets Teleflex boost how much capital we return to shareholders. Crucially, we still foresee M&A chances within the focus areas we've laid out before. And this authorization ought to be seen as supplementing our central capital allocation approach and lets us use our robust balance sheet and cash flow nimbly to fuel shareholder return. When you factor in the $200 million accelerated share repurchase, our pro forma Q2 leverage comes to about 1.9x. That gives us plenty of room for M&A while still maintaining a conservative debt profile. Now for our updated 2024 financial guidance: we're lifting our 2024 adjusted constant currency revenue growth outlook to 4.25% to 5.25%, up from the previous 3.75% to 4.75%, which excludes the impact of the Italian measure from prior years. This increase in revenue guidance is driven by first-half growth that came in stronger than we expected, along with additional intra-aortic balloon pump revenues in Q4. I also want to flag for investors that when we compare this year to last, we're facing a headwind of as much as $75.7 million tied to lost MSA revenues, which is only partly made up for by revenue we've picked up from Palette. Our focus right now is on seizing the balloon pump opportunity, even though that opportunity keeps changing as we go. As things stand today, we're expecting additional IAB revenue during the fourth quarter, and that assumption is built into the updated revenue guidance we gave for 2024. When we look toward 2025, we're anticipating more revenue from IABP and catheters, but the size of that bump and how long it persists will depend on how demand plays out from one quarter to the next. We'll come back with an update as soon as we have a clearer picture of this evolving situation. For the moment, we're assuming the balloon pump opportunity carries on at least through the first half of 2025. Shifting to foreign exchange; we keep assuming a negative foreign exchange effect of about $12 million, amounting to a 40 basis point headwind to GAAP growth in 2024. The guidance bakes in an average euro exchange rate of roughly $1.07 for 2024; on a GAAP basis, which folds in the foreign currency impact plus the $13.8 million for the Italian measure, we anticipate reported revenue growth of 3.4% to 4.4% in 2024, which implies a dollar range of $3.76 billion to $3.105 billion. When you take out the impact of the Italian measure, our revenue growth as reported for 2024 ought to come in at somewhere between 3.85% and 4.85%, translating into a dollar figure of $3.89 billion up to $3.119 billion. That revenue band, once the Italian measure is excluded, is what our 2024 guidance is built around. Keep that in mind as you build your models. For the 2024 outlook, we've baked in $765 million to $770 million of revenue for Q3, which equates to year-over-year growth of 3.1% to 3.7%, after factoring out an FX drag slightly larger than $4 million; and at both the bottom and top of the range, our 2024 gross margin guidance goes up by 25 basis points, bringing it to between 60.25% and 61%. That bump is due to how well operations did during the first six months of 2024, plus what we anticipate will be a pickup in capital equipment orders during Q4, driven by intra-aortic balloon pumps. When it comes to pumps, the capital portion does drag down our overall corporate gross margin a bit. That said, as we sell more disposables, or catheters, which come with better margins, we anticipate the margin picture will get better down the road. We're also raising our operating margin outlook by 25 basis points at both the low and high ends, which brings it to a range of 26.5% to 27% for 2024. The forecast we're providing takes into account how gross margin carries through, along with benefits from our restructuring efforts. Those positives are partly offset by expenses tied to running Palette Life Sciences and by spending aimed at expanding the business. Now turning to the items below the line: for 2024, we anticipate net interest expense will come in around $81 million. That figure factors in the extra borrowing tied to the $200 million ASR we announced today. Most of the anticipated year-over-year rise in net interest expense stems from debt taken on for the Palette acquisition and from elevated interest rates, with scheduled repayments of debt during 2024 providing some offset. As for our tax rate, we still look for it to land near 12% in 2024, reflecting the effect of the Pillar 2 global minimum tax. Now, on to the financial results. We're lifting the bottom end of our guidance by $0.20, and the top end by $0.25. That takes into account the IABP opportunities we talked about earlier, along with how we performed in the first half. So for 2024, we're now projecting adjusted earnings per share between $13.80 and $14.20. Our outlook for 2024 adjusted EPS still includes $0.87 of headwinds compared to last year. Once you strip those out, underlying adjusted constant currency EPS growth year over year comes to roughly 9% at the low end of guidance and 11% at the high end. That wraps up my prepared remarks, and I'll hand things back to Liam for some closing comments.
Liam Kelly
executiveThank you, Tom. To wrap up, let me point to 3 main messages from Q2 of 2024. To begin, durable expansion came during the second quarter because of our varied portfolio and worldwide reach. Strong execution continues to be the case for us. New products are being introduced, and our margins are still at healthy levels. Next, the combination of a strong first half performance and the contribution we anticipate from the intra-aortic balloon pumps in Q4 gives us the confidence to raise our guidance for revenue and earnings per share for 2024. Last, our attention will stay on the strategy meant to produce durable growth. Results from Palette are exceeding what we expected. We are moving forward with the opportunity in intra-aortic balloon pumps and catheters. And Titan is delivering solid growth. Organic growth opportunities will receive investment from us as we push innovation forward and widen our margins. And finally, our disciplined capital allocation strategy will be carried out, which now features a share repurchase program aimed at returning cash to shareholders and boosting long-term value creation. That brings my prepared remarks to a close. At this point I would like to hand the call back to the operator for Q&A.
Anthony Petrone
analystCongratulations on a great quarter here.
Liam Kelly
executiveThanks, Anthony.
Anthony Petrone
analystLet's perhaps begin with intra-aortic balloon pumps — there's been plenty of chatter out there, Liam. You brought up that May 8 notice regarding the competitor. Perhaps share what you're picking up on the ground; it appears that, judging by the competitor's results, the second quarter didn't show much movement. Your guidance anticipates some market shift, possibly beginning in the back half of this year and carrying into 2025. But perhaps just tell us what you're hearing on the ground concerning intra-aortic balloon pumps. And if possible, perhaps size that opportunity for us across the coming 12 to 18 months; then I'll ask a follow-up.
Liam Kelly
executiveYes, Anthony. Well, to begin, we're very pleased that we can raise our total revenue guidance for the year by 50 basis points. A major driver of that is the intra-aortic balloon pump opportunity, which we anticipate landing in the fourth quarter. When it comes to intra-aortic balloon pumps and catheters in particular, across the last 2.5 years, Anthony, our market position has been really strong; and up to now we've kept gaining share. That opportunity is shifting in real time, and given what we know today and the visibility available to us, we do anticipate that the large majority of those pumps will ship during Q4 — purely a matter of timing, Anthony, in the marketplace, since it takes time for people to move them through their system and place orders. I can tell you our quote rate has been extremely robust ever since the competitor's announcement, and it's encouraging enough that we recognize this will have an effect at least through the first half of 2025. On the ground, you get a range of responses from customers. Most of the inbounds have originated from north — the U.S. in particular, not North America, and not a great deal from Europe, since the CE mark at present has been suspended only for a shorter stretch of time. In Asia Pacific we were gaining share all along, and we anticipate that continuing across a multiyear period. Our aim is to make sure that, over the longer term, this isn't solely about pumps — the catheters that come after those pumps will stay with us across a multiyear period. And our second aim is to make sure that whatever share we capture, we hold onto it over the long term, so we grow into a more significant player in the intra-aortic balloon pump and catheter market.
Anthony Petrone
analystAnthony, that's helpful. One quick follow-up: as we look at the share gains in that category, what can you say about the margin profile of that incremental share gain? What kind of margin tailwind should pumps give us? Then just a quick one on capital allocation and the share buyback; maybe walk through the tuck-in M&A strategy versus buyback. Does this point to a shift away from tuck-in strategy, more toward buyback? And how do you weigh those 2 priorities?
Liam Kelly
executiveLiam, thanks, Anthony. I'll take the second question first, Anthony, since I think it's an important one. As Tom and I both said in our prepared remarks, this comes on top of our ongoing M&A strategy. Right now, if you take a look at our business, the amount of free cash flow we're producing is extremely robust. Our leverage currently sits at 1.6x. Once you factor in the $200 million from the ASR, we move up to 1.9x, which is a very solid place to be. We're still out there actively pursuing opportunities in the M&A market. For every investor on this call, I want to make clear that none of this slows us down at all when it comes to our M&A strategy, and we'll keep putting money into the business to drive better shareholder return. On your first questions, Anthony, regarding the margin profile, my answer would be that you really need to view it across 2 buckets. Initially, we'll absorb the pump sales, especially starting in Q4, as I mentioned before. Those pull down our overall company margin. Later, the catheters bring a boost to that same average. Taken together, the whole segment matches our company average, yet it arrives in two phases. Pumps come through first, and across the following several years, the higher-margin catheters show up. That's the way to build your forecast. Let me add one more thing there. Even with the pump volume landing in Q4, we've still managed to raise our gross margin guidance by 25 basis points, and that came from the core business. That ought to make it very clear to our investment community that the core business is doing exceptionally well — it's what's producing the 25 basis points in gross margin, the 25 basis points in operating margin, and of course the EPS Tom described in his remarks.
Matthew O'Brien
analystTo build on what Anthony mentioned about IABPs, Liam — does it make sense to break it down this way? Full-year guidance sits near $15 million, with roughly $10 million tied to IABPs alone, and that figure covers only the U.S. Looking at the market, the untapped Stateside opportunity for you appears to be around $60 million. So effectively, you expect to capture roughly a sixth of that in Q4, with additional share coming through next year. Is that the correct framework? Also, given that the CE mark has been suspended, why wouldn't Europe represent an opening as well?
Liam Kelly
executiveYes. Thanks. My view, Matt, is that this situation keeps shifting as we speak. Keep in mind it only occurred on May 8. Inbound volume for our cold didn't begin climbing meaningfully until late June was well underway. Now it's August 1, so that gives you a sense of the timing. I'm simply laying out a chronology. As I see the call-up, the bulk of it relates to the intra-aortic balloon pumps. Catheters will follow at a later point. I share your view that additional opportunity exists to build and capture greater market share, at minimum during the first half of 2025. On Europe, near term — we've seen short-term suspensions before involving the competitor being absent from the market. Going back to 2023, they were gone for 6 months. Very little volume shifts over a brief window, Matt. That's the reason we're holding back our expectations for Europe, unless the CE mark withholding stretches past that period. And as I mentioned, in a situation that keeps evolving, that picture would shift. I'd add that we've started ramping up manufacturing and will keep doing so, ensuring we can meet demand. As of today, I'm quite confident we can satisfy any demand arising from this opportunity, simply given how the manufacturing process works for the pumps as well as the catheters.
Jayson Bedford
analystI really don't want to keep going down this path about the balloon pump, but real quick—regarding that $250 million market you mentioned, can you split it between capital and single-use disposables?
Liam Kelly
executiveWhat I'd tell you is, if you wanted to break that $250 million apart, Jayson, the simplest way to think about it is roughly 50/50. On a yearly basis, half of it is generated by the capital side. Just keep in mind that pumps typically last around 8 years, while the catheters are consumed across that same period. So for the $250 million, that's a fair rule of thumb.
Jayson Bedford
analystAll right. And perhaps for Tom, regarding the guidance and EPS — you came in above 2Q. You raised the margin outlook, yet out of that $0.20 to $0.25 EPS increase, what portion ties back to the buyback?
Tom Powell
executiveSure. When we look at that $0.20 to $0.25 raise, it's genuinely an organic gain; it stems from how the core business is performing. Considering the various positives and negatives, we'll see some added IABP revenues, which we expect will counterbalance the effect of the Italy payback. Meanwhile, the higher interest expense tied to the buyback gets offset by fewer shares outstanding. So during 2024, the buyback on its own should be EPS neutral, since the extra interest expense incurred is cancelled out by a lower average weighted share count. So once more, that $0.20 to $0.25 stems from the underlying organic business's strength.
Liam Kelly
executiveLet me just add this, Jayson — the upside from buying back shares is something we'd expect to show up in 2025.
Shagun Singh Chadha
analystLiam, could you bring us up to speed on interventional urology with a bit more granularity? How much did M&A add this quarter? And on the UroLift side, what are you observing when it comes to doctors' offices?
Liam Kelly
executiveSure thing, Shagun. Where doctors' offices are concerned, what I can say is that things remain difficult; the picture looks a lot like Q1, so there's been no real shift in how growth is trending across sites of service, no difference in how many procedures happen in offices rather than hospitals, and honestly no movement in the office growth trajectory either. It's still a challenging area. What I can point to, as we laid out in our prepared remarks, is Palette as the place where the most has changed: given how Palette Life Sciences has performed over the first half of the year, and Barrigel specifically, our revenue guidance is being raised from $66 million to $68 million, up to $70 million, $72 million. Where UroLift is concerned, results have largely tracked in line, though for interventional urology we're by definition keeping our full year guidance at 7.5%. And Palette's results make us very happy, as does Barrigel's performance. Cross-training is finished now, Shagun, for those 50 dual-bag reps. And just as our full year guidance always assumed, with no revision, we continue to expect things to improve over the second half as Palette Life Sciences keeps ramping and those dual-bag sales reps get back out in the field selling both products.
Shagun Singh Chadha
analystUnderstood. Then, as a second question for Tom: could you walk us through how margins will trend during the latter half? In particular, you brought up IABP. The capital piece will play a role. And then, how do you compare with your earlier LRP, which sat at the bottom end for gross and operating margins — 61.5 and 28.75%?
Tom Powell
executiveSure, I'd say that, picking up on what Liam mentioned, the margin characteristics of the added revenue coming from the IABPs are a bit dilutive versus our company-wide average. What we anticipate across the second half is a gross margin that stays fairly steady in Q3 and Q4; and where operating margin is concerned, additional leverage should show up in Q4 simply because revenues will be stronger. So once more, when we look further out at the IABP chance, during 2025, with more catheters being sold, that business's margin profile will begin to improve. As for the LRP, our view remains that these targets suit the company well. On gross margin, I'd note there's a route to reaching it. Strong mix, solid results from our manufacturing sites, and inflation that keeps getting better will all be necessary for us to arrive there, yet these remain targets we're still pursuing; and we'll give you an update at the right time when we reach 2025 guidance.
George Sellers
analystPerhaps regarding the Ringer balloon catheter topic. Could you provide a bit more information about how that expands what you already offer; roughly where it slots in; and what you anticipate when it comes to share movement over time plus any cannibalization affecting your current line of balloon catheters?
Liam Kelly
executiveThank you, George. Ringer carries a PTCA indication, and that sits squarely within the target audience for the largest portion of our reps who handle our complex catheters; it's expanding toward a market worth roughly $40 million; and as I mentioned, its indication is PTCA. Our view here is that further indications could emerge in the peripheral space. And as everyone knows, we have one heart and 2 legs, meaning the peripheral market is considerably larger. What I expect is that surgeons along with interventional cardiologists will point us toward the next use. Once they have this product in hand, it's quite an innovative offering. Essentially, what this product accomplishes is assisting interventional cardiologists when an unintended vessel puncture occurs. And it enables them to keep performing the procedure through use of the Ringer catheter. There won't be any cannibalization, George, regarding that portion of your question about our existing portfolio. And we've recently finished a perforation study, which will serve as the subsequent indication for this product as we keep expanding into that $40 million market. So that's yet another illustration of innovation happening inside the interventional access business. Fresh products entering this business especially represent the lifeblood of interventional cardiology. You need to be present before the clinician in the cath lab, and carrying new products in your bag makes that ongoing interaction possible. We've witnessed this with MANTA and we've witnessed this with the Wattson wire. Now we're about to witness it with Ringer; and we're truly pleased that this product arrived — slightly ahead of its scheduled timeline. So we're also pleased with how the R&D organization executed within that business unit, George.
George Sellers
analystAll right, excellent. That's genuinely useful context, and I appreciate it. Perhaps if we turn our attention once more to interventional urology, I'm simply wondering whether the training you mentioned — the one that has now wrapped up — carries any effect we could actually measure. To what extent did that act as a drag, if it did at all? And how should we frame possible drags or quarter-over-quarter lifts related to training in that area moving ahead?
Liam Kelly
executiveHonestly, putting a number on what it did during the first six months is tough, though the consequences of cross-training were something we'd built into our plans. We understood it would leave a mark, and because of that, we consistently expected interventional urology to show gains as we progressed toward the latter portion of the year. In my view, George, those lifts arrive through 2 channels. First, you've got additional sales reps in the field now discussing Barrigel, which represents an opening. Second, as you're aware, both Barrigel and the Palette portfolio are scaling up during the second half as time goes on. Once more I'd like to emphasize how happy we are to report the 4 million on Barrigel, purely on the strength of how the first half went. The remaining lift you'd anticipate comes from those reps who'd been occupied with training across quarter 1 and quarter 2 getting back onto the road, again promoting and — bringing UroLift back to their surgeons — so we'd look for some degree of gain there too, exactly as had always been expected, George. And our guidance for interventional urology stays at 7.5%, so our confidence in hitting that figure is solid.
Vikramjeet Chopra
analystThis is Vik, sitting in for Larry. To start, M&A has historically played a big part in driving your revenue growth. Could you share what you're seeing right now on the M&A side? Also, do you lean more toward price-to-sales deals or EBIT-to-EBITDA deals? If that's the case, which areas? Then I have one more question after that.
Liam Kelly
executiveSure, Vik. Naturally, we're busy in the market; we're constantly busy in the market. At any given moment, there are multiple assets we're pursuing and watching very carefully. Our leverage works in our favor. Even with the $200 million on the ASR, we sit at 1.9x pro forma. And in my view, the M&A backdrop has gotten better for private assets. On valuations, I've noticed expectations around valuation easing somewhat. Within the segments we target, it's the worst kept secrets that the cath lab is something we really like as a cold point. Emergency medicine is something we really like. For our vascular team, the intensive care unit is — each and every day, a focus area for us; tuck-ins in OEM and in surgical are things we could pursue. I want to say again that the share repurchase does not replace M&A. Alongside the share repurchase, we are going to do M&A. We can handle both, and our cash flow generation supports both; plus, for us, the share repurchase is simply one more method of returning capital to our shareholders; we keep supporting our dividend; we keep reinvesting in the business, and certainly, we plan to keep doing really good M&A. The second half of your question is tough to answer, Vik. "Are the assets you're chasing dilutive or accretive?" Looking at the spectrum we cover, we recognize that dilution isn't a favorable outcome. And we're examining assets that keep adding value on the top line as well as to earnings, and those assets exist and can be acquired.
Vikramjeet Chopra
analystThanks. One more question about the ASR. What's your expected timeline for finishing it? I believe you mentioned — or perhaps it was Tom — that the bigger effect lands in 2025. And will the ASR deliver double-digit growth in the coming year?
Tom Powell
executiveThe ASR should take 2 to potentially 3 months to wrap up. We plan to get it started fairly soon; regarding next year's growth, we'll hold off until our 2025 guidance to address that fully, but on the idea of more benefit arriving in 2025, that stems from the way weighted average shares get calculated since it wasn't part of our opening figure. Once we're in 2025, the share impact I'll see will be larger than what we're seeing in 2024, though as Liam noted, the earnings benefit comes in 2025; we'll go over all of it at our Fourth Quarter Earnings Call when we give guidance for the year.
Richard Newitter
analystWe've got a few calls going at once here. If someone already covered this, I'm sorry, but let's begin with the pumps — the IABP opportunity. You mentioned a lot of quoting activity. How confident are you that those quotes can be turned into actual wins or share gains? We'd really like to hear about that. Then I want to confirm I've got the margin effect straight versus what happens to earnings and revenue. So at the outset, IABP share gains will carry lower margins because of the capital component. Is that accurate?
Liam Kelly
executiveThat's right, Rich. This business overall matches the company's gross margins. The capital part sits a bit lower, while the catheter part sits a bit higher, so taken as a whole, it's equal. But the 25 basis points of gross margin improvement isn't coming from the intra-aortic balloon pumps. It's actually happening in spite of them — on the margins. It isn't much of a drag, since it's only slightly below, but I want everyone to understand that the lift in gross margins and op margins truly comes from the core business and how the core business is performing. As for your question, which is a good one, about our ability to turn those quotes into sales — well, previously, there were 2 possible suppliers of product in the marketplace. Our conversion rate matched our market share, and — but it was rising. The whole market is expanding at roughly 3% or 4%. Over the past several years, our intra-aortic balloon pump and catheter business has grown at over twice that market share growth. So we have been — we've kept taking share, especially in the U.S. and in Asia Pacific. The quote volume I mentioned, Rich, is entirely within the United States, where the FDA has strongly advised customers to find another supplier. And our confidence in converting that quote volume tied to the call-up in Q4 is extremely high, given the activity we're seeing.
Richard Newitter
analystAll right. Then regarding the payback add-back — that Italian line item being included again in adjusted revenue — could you walk through how that works, and the reason a reserve adjustment is being added back?
Liam Kelly
executiveRich, I’ll have Tom address that.
Tom Powell
executiveAbsolutely, Rich. So when you look at the second quarter overall, we’re recording extra reserves amounting to $15.8 million. Of that figure, $13.8 million comes from a true-up tied to reserve amounts established in earlier periods. The other $2 million reflects further reserves connected to 2024. That means the add-back restores the prior-period portion—the $13.8 million—to the reserve. The main reason we’re doing this is that we don’t view it as belonging to 2024’s continuing operating results. We also wanted to give visibility into how the business is doing this year. That’s essentially the rationale and how it works mechanically. I hope that addresses your question. If it doesn’t, I’d be glad to offer additional detail.
Liam Kelly
executiveAnd Rich, let me tack just a little onto what Tom said. I want everyone clear that during the present year, in Q2 — since, as you know, this didn't take place until July — when we totaled things up for Q2, we came in above the upper limit of the guidance we'd given, which ran from $760 million to $765 million. Then, after the quarter had closed in late July, we recorded a booking worth $2 million, and there's a further $2 million of effect in the second half of the year that we're booking, since it falls in the current year. My view is that this ought to be something the company books in real time. And like Tom mentioned, the remaining $13.8 million pertains to earlier periods, so it wouldn't fairly reflect how the company performed.
Mike Polark
analystI want to ask a second question about balloon pumps, and then I have another one. Regarding the balloon pump, is the consumable tied to the pumps themselves, or is that consumable market open to anyone? That's my first question. And then, since this market is sort of balancing on sole sourcing right now, given the difficulties your competitors are facing, do you think there will be a pricing element when you convert these orders, compared with what has historically been the case in this market?
Liam Kelly
executiveTo start with the catheters, the rate at which they attach to the actual pump brand is extremely high. Traditionally, if you were using a competitor's pump, you were using that competitor's catheter. That's all wrapped up in how the decision gets made. And if you were using the Teleflex pump, you were using the Teleflex catheter. Each company offers adapters that do a decent job of converting catheters, though not as well, since the catheters function in different ways. What I mean by that is that our fiber optic catheter carries a sensor at its tip, and that's what allows it to pulse. With the competitor catheter, the sensor sits inside the pump, and that's what allows it to sync; as a result, they don't perform as well on the fiber optic lasers, and so the attachment rate for a given catheter brand is extremely high relative to whichever pump brand the customer is using. When it comes to price, we typically are dual sourced across many of these IDNs, where you'll find hospitals within a single IDN. Some of them will be using the competitor's pumps. Some will be using our pump. So pricing agreements are already in place, which means I don't expect any significant price increases as we convert the market. And honestly, our focus is on the long term when it comes to converting the market and holding a much stronger share position across a 12-month period, sustaining that position, and sustaining the catheters across a multiyear period.
Mike Polark
analystThanks, Liam. As a follow-up, I'd like to get a clearer picture of why the GAAP earnings per share guidance came down. The restructuring line appears to be where the increase sits, so is there anything meaningful worth flagging there?
Liam Kelly
executiveIf it's alright with you, I'll have Tom walk us through the gap.
Tom Powell
executiveNo, there's nothing really to call out. Yes, yes.
Liam Kelly
executiveOkay, business as usual, Mike. Thanks for the questions.
Craig Bijou
analystCraig, following up on interventional urology, plus a quick one on M&A: given how well Palette has done and the guidance increase, I'm curious whether the growth trajectory for that business changes — I believe you'd been thinking mid-20s growth at the midpoint? And I realize interventional urology guidance was left unchanged, but with Palette contributing 4 million more, that implies UroLift drops by 4 million. Or perhaps there's upside. So is there anything on the international UroLift side worth mentioning?
Liam Kelly
executiveLiam: Craig, your math checks out — that's correct — but Palette's outperformance has us quite encouraged. You're also right that this year's growth rate will exceed what we initially expected. We had anticipated high-teens to low-20s, in the 20s. Looking at the pro forma, we exceeded $56 million last year. At the midpoint, we'll hit $71 million, which puts you around 25% growth — very, very encouraging on that front. What matters to understand is that we keep converting the white space, bringing this product to our existing customer base, and educating radiation oncologists about the need for spacing. Spacing overall is growing, so that's the positive. On interventional urology abroad, I'll say the results we're seeing for UroLift in Japan are incredibly encouraging; we keep penetrating that market. Also in Japan — and I mention Japan specifically since it's the biggest next market internationally — what I'd highlight is that we expect Barrigel approval there in the first half, probably of 2025. That would give us a nice opportunity to keep expanding Barrigel. We're also starting patient enrollment for the study for an expanded indication. We believe that will grow the Barrigel market by roughly $100 million. The next biggest overseas market with potential is probably China. We keep seeding the Chinese market as we keep trialing the product in some of the larger provinces there, to get it on the tender system, Craig. Thanks for the question.
Craig Bijou
analystCraig, understood. Let me jump in briefly on the M&A point, regarding the buyback authorization and the ASR, following up on what I think was Vik's question. Perhaps you're wondering whether having that repurchase program in place makes us more inclined to accept some dilution from acquisitions, since we could use it to counter the hit to the bottom line.
Liam Kelly
executiveWell, here's the thing: once you've looked at a single deal, you've basically looked at one deal, Craig — that's simply how it goes. At any given moment, we're pursuing a small number of targets, and no two are alike. Each one gets evaluated on its own terms. Honestly, I don't see us treating the buyback as some kind of offset. Every target stands or falls on its own merits, and we examine particular return metrics. Beyond that, we pay very close attention to how accretive or dilutive a deal is to earnings per share when we pursue M&A, and that consideration definitely plays into what we acquire. Everyone recalls that Palette diluted us, yet today Palette shows a call-up of 4 million at margins exceeding those of UroLift and far above the corporate average. So it's clear that Palette, once it turns accretive in 2025, is going to add to EPS. We do owe shareholders an apology for the year-long wait before that accretion arrives, but the fundamental EPS growth, as Tom laid out during his prepared remarks, now sits at 9% to 11%, giving us strong visibility into dependable EPS performance. Once more, Craig, I appreciate the questions.
Dave Turkaly
analystI've got 2 quick questions about EMEA, your second biggest region. I believe you mentioned more capacity or supply, plus improved utilization, correct? I'd like to know how and where that happened, if you can speak to it. Then, regarding the growth rate you reported, how sustainable do you feel that is?
Liam Kelly
executiveYes, thank you so much, Dave. What I can say is that EMEA delivered a very solid quarter, with growth of 9.8%. Where is that coming from? We performed really well in Germany, France and Spain. In Italy, we were actually very strong too. We also booked the $2 million during the quarter, which brought it down to a lower level. On the product side specifically, we saw really strong results in emergency medicine, interventional urology and interventional access. What I find very encouraging in Europe is that — within interventional access, MANTA keeps penetrating that market. We were there a couple of years before we even entered the United States, so that's quite encouraging in that market. The other part of your question is whether it's sustainable. EMEA hasn't grown at these levels forever. I think we'd expect the rest of this year to be strong, perhaps not quite at these levels, but over the longer term we'd expect EMEA to be in the mid-single-digit growth; and given how this team is executing, maybe climbing into the higher mid-singles. But we'll map that out as we go through our guidance for next year; but really encouraged by what we're seeing; and those are the geographies, Dave, that we're seeing in it.
Dave Turkaly
analystThat is the reason I raised that question, but yes, it is nice to hear that.
Larry Keusch
executiveThanks, Kayla. And thanks to all of you who were with us on today's call. That brings the Teleflex Incorporated Second Quarter 2024 Earnings Conference Call to a close.
Operator
operatorAnd you may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.